---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107180"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:07:56.260012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI

## Summary
- Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.
- Revenue $11.8M, down from $24.1M YoY due to sale of Huntsville facility in Dec 2024.
- Cash & marketable securities $270.2M as of Sep 30, 2025; includes $107.2M from July secondary offering.
- R&D expense $27.3M vs $35.0M YoY; focus on rezpegaldesleukin, NKTR-0165, NKTR-422.
- FDA granted Fast Track for rezpegaldesleukin in severe alopecia areata; topline data expected Dec 2025.

## SEC filing metadata
- accession: 0001213900-25-107180
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025107180/0001213900-25-107180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025107180/ea0264261-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107180
- JSON: https://secwatch.observer/filing/0001213900-25-107180.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.